Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04916002
Title CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Checkmate Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS


No variant requirements are available.